JP2014139255A5 - - Google Patents

Download PDF

Info

Publication number
JP2014139255A5
JP2014139255A5 JP2014097072A JP2014097072A JP2014139255A5 JP 2014139255 A5 JP2014139255 A5 JP 2014139255A5 JP 2014097072 A JP2014097072 A JP 2014097072A JP 2014097072 A JP2014097072 A JP 2014097072A JP 2014139255 A5 JP2014139255 A5 JP 2014139255A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
tissue
nitrite
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014097072A
Other languages
English (en)
Japanese (ja)
Other versions
JP5908527B2 (ja
JP2014139255A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014139255A publication Critical patent/JP2014139255A/ja
Publication of JP2014139255A5 publication Critical patent/JP2014139255A5/ja
Application granted granted Critical
Publication of JP5908527B2 publication Critical patent/JP5908527B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014097072A 2007-11-15 2014-05-08 慢性虚血における亜硝酸塩の使用 Expired - Fee Related JP5908527B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US315007P 2007-11-15 2007-11-15
US61/003,150 2007-11-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010534267A Division JP5795165B2 (ja) 2007-11-15 2008-11-17 慢性虚血における亜硝酸塩の使用

Publications (3)

Publication Number Publication Date
JP2014139255A JP2014139255A (ja) 2014-07-31
JP2014139255A5 true JP2014139255A5 (cg-RX-API-DMAC7.html) 2014-09-11
JP5908527B2 JP5908527B2 (ja) 2016-04-26

Family

ID=40639493

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010534267A Active JP5795165B2 (ja) 2007-11-15 2008-11-17 慢性虚血における亜硝酸塩の使用
JP2014097072A Expired - Fee Related JP5908527B2 (ja) 2007-11-15 2014-05-08 慢性虚血における亜硝酸塩の使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010534267A Active JP5795165B2 (ja) 2007-11-15 2008-11-17 慢性虚血における亜硝酸塩の使用

Country Status (7)

Country Link
US (2) US9649334B2 (cg-RX-API-DMAC7.html)
EP (1) EP2219657A4 (cg-RX-API-DMAC7.html)
JP (2) JP5795165B2 (cg-RX-API-DMAC7.html)
CN (1) CN101939014B (cg-RX-API-DMAC7.html)
AU (1) AU2008322437B2 (cg-RX-API-DMAC7.html)
IL (1) IL205720A (cg-RX-API-DMAC7.html)
WO (1) WO2009065142A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008322437B2 (en) 2007-11-15 2013-11-07 Louisiana State University Use of nitrite salts in chronic ischemia
US8568793B2 (en) * 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20120237617A1 (en) 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
US20130209584A1 (en) * 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
ES2633618T3 (es) 2009-10-14 2017-09-22 Theravasc Inc. Formulaciones farmacéuticas de nitrito y sus usos
WO2014130691A2 (en) * 2013-02-20 2014-08-28 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
ES2968200T3 (es) 2016-01-27 2024-05-08 Syk Tech Llc Aparato y métodos de aplicación tópica de óxido nítrico
JP7333919B2 (ja) 2017-09-05 2023-08-28 エクセル メッド、エルエルシー 虚血を治療するためのヘパリン組成物
PH12021551384A1 (en) 2019-01-02 2022-03-28 Celagenex Res India Pvt Ltd Synergistic nutritional compositions for pain management
US12459820B2 (en) 2020-06-11 2025-11-04 J. W. Randolph Miller Stabilized and NO2-inhibited nitric oxide generating gels for inhaled nitric oxide therapy

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914446A (en) 1958-06-26 1959-11-24 Upjohn Co Nitrite stabilized ascorbic acid-cyanocobalamin compositions
US4650484A (en) 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5122384A (en) 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
US20110196039A9 (en) 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5994444A (en) 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US7015876B1 (en) 1998-06-03 2006-03-21 Lear Corporation Heads-up display with improved contrast
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
WO2000003725A1 (en) 1998-07-14 2000-01-27 Paracelsian, Inc. Method for identifying and confirming consistent bio-functionality of natural compositions
DE59905248D1 (de) 1999-01-29 2003-05-28 Disphar Int Bv Pharmazeutische zusammensetzungen
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
US6314956B1 (en) 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
WO2002009727A1 (en) * 2000-07-28 2002-02-07 Bioenergy, Inc. Compositions and methods for improving cardiovascular function
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
EP1492509A1 (en) 2001-12-18 2005-01-05 ALZA Corporation Dosage form providing time-varying patterns of drug delivery
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CA2379211A1 (fr) 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
JP5564158B2 (ja) 2003-07-09 2014-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 亜硝酸塩によって特定の心臓血管状態を処置する方法
JP2007502831A (ja) 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
CN101227916A (zh) 2005-05-24 2008-07-23 维尔金有限公司 预防和治疗发炎相关状况的组合物和方法
BRPI0621321A2 (pt) 2006-02-10 2011-12-06 Mannatech Inc formulações de suplemento dietético de multivitamìnico e multimineral natural para melhor absorção e utilização biológica
GB0607402D0 (en) * 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
US8333997B2 (en) * 2006-06-21 2012-12-18 Albert Einstein College Of Medicine Of Yeshiva University Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
KR20100014853A (ko) * 2007-02-26 2010-02-11 존 런드버그 아질산염 및 질산염의 신규 용도 및 이를 함유하는 조성물
DK2124638T3 (en) 2007-02-26 2017-03-20 Heartbeet Ltd COMPOSITION INCREASING PERFORMANCE AND USING IT
WO2008153762A2 (en) 2007-05-25 2008-12-18 N30 Pharmaceuticals, Llc S-nitrosothiol formulations and storage systems
AU2008322437B2 (en) 2007-11-15 2013-11-07 Louisiana State University Use of nitrite salts in chronic ischemia
EP2237788A4 (en) 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF
WO2010036236A1 (en) 2008-09-23 2010-04-01 Baker Hughes Incorporated Anchor assembly
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20120237617A1 (en) 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
ES2633618T3 (es) 2009-10-14 2017-09-22 Theravasc Inc. Formulaciones farmacéuticas de nitrito y sus usos
US20130209584A1 (en) 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
US20140127329A1 (en) 2011-03-31 2014-05-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
US20140112983A1 (en) 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
US9294956B2 (en) 2011-12-29 2016-03-22 Qualcomm Incorporated Application-server-assisted preemptive multicast bearer establishment for real-time low-latency applications
WO2014130691A2 (en) * 2013-02-20 2014-08-28 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof

Similar Documents

Publication Publication Date Title
JP2014139255A5 (cg-RX-API-DMAC7.html)
JP2011503212A5 (cg-RX-API-DMAC7.html)
JP2020033360A5 (cg-RX-API-DMAC7.html)
JP2021504423A5 (cg-RX-API-DMAC7.html)
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
JP2020534270A5 (cg-RX-API-DMAC7.html)
JP2024540183A5 (cg-RX-API-DMAC7.html)
FI3716979T3 (fi) 4-pyrimidiinisulfamidijohdannaisen ja SGLT-2-inhibiittorin yhdistelmä endoteliiniin liittyvien sairauksien hoitamiseksi
JP2015526458A5 (cg-RX-API-DMAC7.html)
JP2019517542A5 (cg-RX-API-DMAC7.html)
JP2014077003A5 (cg-RX-API-DMAC7.html)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JOP20220058A1 (ar) بروتينات اندماج علاجية
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法
JP2022545156A5 (cg-RX-API-DMAC7.html)
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
RU2014112324A (ru) Применение органического соединения для лечения синдрома нунан
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
EA201792565A1 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
JP2019529569A5 (cg-RX-API-DMAC7.html)
RU2020120876A (ru) Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение
JP4839309B2 (ja) 血栓症治療剤
RU2016103098A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
RU2012107483A (ru) Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек